Diversified Trust Co Decreases Position in DexCom, Inc. $DXCM

Diversified Trust Co lowered its position in DexCom, Inc. (NASDAQ:DXCM) by 45.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,798 shares of the medical device company’s stock after selling 8,051 shares during the quarter. Diversified Trust Co’s holdings in DexCom were worth $659,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in DXCM. Andra AP fonden purchased a new position in DexCom during the 2nd quarter valued at about $26,000. Twin Peaks Wealth Advisors LLC acquired a new stake in shares of DexCom in the second quarter valued at approximately $26,000. Anderson Financial Strategies LLC purchased a new position in shares of DexCom during the 1st quarter worth approximately $37,000. Sound Income Strategies LLC raised its position in shares of DexCom by 83.8% during the 3rd quarter. Sound Income Strategies LLC now owns 625 shares of the medical device company’s stock worth $43,000 after purchasing an additional 285 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. purchased a new stake in DexCom in the 2nd quarter valued at approximately $45,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on DXCM shares. Argus dropped their price target on DexCom from $100.00 to $90.00 and set a “buy” rating for the company in a research report on Friday, November 7th. UBS Group dropped their price objective on DexCom from $106.00 to $95.00 and set a “buy” rating for the company in a research report on Monday, November 3rd. TD Cowen cut their target price on shares of DexCom from $100.00 to $84.00 and set a “buy” rating for the company in a research note on Friday, October 31st. The Goldman Sachs Group decreased their price target on shares of DexCom from $104.00 to $89.00 and set a “buy” rating on the stock in a research note on Wednesday, October 1st. Finally, Evercore ISI initiated coverage on shares of DexCom in a report on Tuesday, November 25th. They set an “in-line” rating and a $68.00 price target for the company. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $86.61.

DexCom Trading Up 0.3%

NASDAQ DXCM opened at $66.54 on Friday. The company has a market cap of $25.95 billion, a P/E ratio of 36.97, a P/E/G ratio of 1.19 and a beta of 1.48. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $93.25. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.56 and a quick ratio of 1.38. The company has a 50-day moving average of $63.74 and a 200-day moving average of $72.62.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.04. DexCom had a net margin of 15.96% and a return on equity of 30.65%. The firm had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.18 billion. During the same period in the previous year, the firm earned $0.45 earnings per share. DexCom’s revenue was up 21.6% compared to the same quarter last year. As a group, equities analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Transactions at DexCom

In other news, Director Bridgette P. Heller sold 1,012 shares of the company’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $58.07, for a total transaction of $58,766.84. Following the completion of the sale, the director directly owned 27,031 shares in the company, valued at $1,569,690.17. This represents a 3.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, COO Jacob Steven Leach bought 18,200 shares of DexCom stock in a transaction that occurred on Monday, November 10th. The stock was purchased at an average price of $55.04 per share, for a total transaction of $1,001,728.00. Following the acquisition, the chief operating officer directly owned 331,697 shares of the company’s stock, valued at $18,256,602.88. The trade was a 5.81% increase in their position. The SEC filing for this purchase provides additional information. Insiders sold a total of 7,866 shares of company stock worth $448,177 in the last ninety days. Insiders own 0.32% of the company’s stock.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.